MassDevice.com +5 | The top 5 medtech stories for May 18, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters. 5. Medtronic owes spine doc inventor $24m for patent infringement Medtronic must fork over nearly $24 million to the physician inventor behind a group of patents covering a technique for treating spine defects. Dr. Mark Barry sued Medtronic in February 2014 in the U.S. District Court for Eastern Texas, alleging infringement for 3 patents covering a “system and method for aligning vertebrae in the amelioration of aberrant spinal column deviation conditions.” Read more 4. FDA panel recommends approval TransMedics lung transplant device An FDA advisory panel yesterday recommended that the federal safety watchdog approve a device made by TransMedics to keep donated lungs perfused during transport to transplantation procedures. The FDA’s Gastroenterology &Urology Devices panel voted 11-2 that the OCS Lung system is safe; 8-5 that it’s effective; and 9-4 that its benefits outweigh the risks, an FDA spokeswoman told MassDevice.com via email. Read more 3. EuroPCR Roundup: Medtronic’s Resolute Onyx meets primary endpoint in small-vessel trial ...
The Zenith Fenestrated Endovascular Graft (ZFEN; Cook Medical, Bloomington, Ind) has expanded the anatomic eligibility of endovascular aneurysm repair (EVAR) for complex abdominal aortic aneurysms (AAAs). Current data on ZFEN mainly consist of single-institution experiences and show conflicting results. Therefore, we compared perioperative outcomes after repair using ZFEN with open complex AAA repair and infrarenal EVAR in a nationwide multicenter registry.
Concurrent abdominal aortic aneurysm (AAA) and unilateral iliac occlusion is a challenge in the implantation of bifurcated stent grafts (BFGs). The endovascular approach is less invasive than open surgery; the aortouni-iliac (AUI) graft with crossover femorofemoral bypass (CFFB) has many problems associated with extra-anatomic reconstruction. We attempted endovascular aneurysm repair (EVAR) using BFGs in such cases and evaluated the outcomes.
The Viborg Vascular (VIVA) randomised controlled trial described a population screening program for abdominal aortic aneurysm (AAA), peripheral arterial disease (PAD), and hypertension, and provided subsequent lifestyle advice and recommendations for medical and interventional treatment in men aged 65 –74 years.1 Some 50,156 men participated in VIVA, and a significant reduction in all cause mortality was found from 10.8% in the control group to 10.2% in the intervention group after a mean follow up of 4.4 years.
In this edition of European Journal of Vascular and Endovascular Surgery, Jungi et al. report results of strictly open surgical treatment of patients with thrombosed popliteal artery aneurysm (PAA): 55 patients during 10 years, most of them with severe ischaemia, with 16% undergoing amputation at ≤30 days.1 The Bern group are sceptical of endovascular surgery, and have publish ed excellent results of ruptured abdominal aortic aneurysm (AAA) repair performed by open surgery alone.2 They use a similar approach for the treatment of thrombosed PAA.
Abstract This paper presents a case study of a patient that underwent surgery for a ruptured abdominal aneurysm. The postoperative course was complicated by resistant hypertension and tachycardia. A suprarenal mass was detected in the computed tomography scan with radiological suspicion of pheochromocytoma. Few cases of pheochromocytoma coexisting with aneurysms have been reported. Management of cardiovascular stability is crucial in such cases. Despite the lack of evidence, pheochromocytomas might have a role in the etiology of aortic aneurysms.
Gambogic acid prevents angiotensin II‑induced abdominal aortic aneurysm through inflammatory and oxidative stress dependent targeting the PI3K/Akt/mTOR and NF‑κB signaling pathways. Mol Med Rep. 2018 Dec 04;: Authors: Liu Q, Shan P, Li H Abstract Gamboge is the dry resin secreted by Garcinia hanbaryi Hook.f, with the function of promoting blood circulation and anti‑cancer effects, detoxification, hemostasis and killing insects. It is also used for the treatment of cancer, brain edema and other diseases. Gambogic acid is the main effective constituent of Gamboge. The present study teste...
This study aimed to determine the influence of SES on postoperative survival after AAA repair.
In this issue of the European Journal of Vascular and Endovascular Surgery, Gombert et al.1 compare open one stage with two stage repair of type II thoraco-abdominal aortic aneurysm (TAAA). The authors conclude that open two stage repair, if anatomically feasible, demonstrates a lower mortality than and similar complication rates to one stage repair. These findings do not come as a surprise and reflect a current trend in TAAA repair strategy: towards endovascular and hybrid repair and towards two stage repair in order to reduce both mortality and morbidity.
The use of endovascular aneurysm repair (EVAR) for the treatment of infrarenal abdominal aortic aneurysms (AAAs) is now widespread, with the minimally invasive approach, rapid recovery, and better early survival proving attractive to clinicians and patients. Approximately 60% of all AAA repairs in Europe and 85% in the USA are now by EVAR.1,2
The new European Society for Vascular Surgery (ESVS) Clinical Practice guidelines on the management of abdominal aortic aneurysms (AAA) were produced by clinicians for clinicians, but for the first time in the history of ESVS guideline production, the AAA guideline development process included input from patients affected by the recommendations.1 Even from the small patient contribution to these guidelines, and similar patient input to recent AAA repair trials, it is clear that the important outcomes for patients and their relatives may be very different from those usually considered important by vascular surgeons.